Study Details | To assess the safety and tolerability of DSP-5336 in adult patients with relapsed or refractory acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), or acute leukemia of ambiguous lineage |
Protocol Number | DSP-5336-101 |
Phase | I |
Therapeutic Area | Leukemia |
Subject Types | With Medical Condition |
Indication | AML, ALL, acute leukemia of ambiguous lineage |
Principal Investigator | Dr Melissa Ooi |
Investigator Product / Device | DSP-5336 |
Sponsor | Sumitomo Pharma Oncology, INC |